Soleus Capital Management, L.P. Crispr Therapeutics Ag Transaction History

Soleus Capital Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$43.47 - $67.77 $1.84 Million - $2.87 Million	42,400 New	42,400 $2.38 Million
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $4.92 Million - $7.81 Million	-70,214 Reduced 76.14%	22,000 $1.67 Million
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $1.2 Million - $1.71 Million	-10,900 Reduced 10.57%	92,214 $10.3 Million
Q2 2021 Aug 16, 2021	BUY	$100.84 - $161.89 $10.4 Million - $16.7 Million	103,114 New	103,114 $16.7 Million
Q1 2021 May 17, 2021	SELL	$110.72 - $210.04 $1.2 Million - $2.27 Million	-10,825 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$79.67 - $173.23 $49,793 - $108,268	625 Added 6.13%	10,825 $1.66 Million
Q3 2020 Nov 13, 2020	SELL	$78.5 - $100.64 $549,500 - $704,480	-7,000 Reduced 40.7%	10,200 $853,000
Q2 2020 Aug 14, 2020	BUY	$38.5 - $76.05 $30,800 - $60,840	800 Added 4.88%	17,200 $1.26 Million
Q1 2020 May 15, 2020	SELL	$33.68 - $62.53 $198,712 - $368,927	-5,900 Reduced 26.46%	16,400 $696,000
Q4 2019 Feb 14, 2020	BUY	$36.68 - $73.13 $817,964 - $1.63 Million	22,300 New	22,300 $1.36 Million

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.23B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.